Home
About Us
Company Overview
Company Highlights
Company History
Our Reach
Our People
Awards and Recognition
Contact Us
Positions Vacant
Legal Disclaimer
Products
Aridol
Bronchitol
Respiratory Diseases
Compassionate Use Programs
Scientific Publications
Patents
Investors
ASX Announcements
News
Quarterly Reports
Annual Reports & Reviews
Investor Presentations
Share Price
Shareholder Services
Join our e-mailing List
Contact Us
Events Calendar
Investor Fact Sheet
Financial Summary
Analyst Coverage
Shareholders
Corporate Directory
Corporate Governance
SEC Filings
News and Media
Media Releases
Quarterly Reports
Media Contact
Research
Product Pipeline
Development Status
Clinical Trials
Investigator-Initiated Studies
Clinical Development
Strategic Alliances
Respiratory and inflammatory diseases
Scientific Publications
Clinical Trial, Regulation & Approval Process
Patents
Useful Information
Glossary
Conditions of Use
Contact Us
Health Professionals
Compassionate Use Programs
Clinical Trials Participation
Investigator - Initiated Studies
Patients
Aridol Test Information
Patient Profiles
Compassionate Use Programs
Clinical Trials Participation
Respiratory Disease
Medical Information
Distributors
Health Professional
Distributors
Patients
Product Pipeline
Development Status
Clinical Trials
Investigator-Initiated Studies
Clinical Development
Strategic Alliances
Respiratory and inflammatory diseases
Scientific Publications
Clinical Trial, Regulation & Approval Process
Patents
Pharmaxis Home
Research
Respiratory and inflammatory diseases
Respiratory and inflammatory diseases
Pharmaxis’ research is targeting treatments for the following diseases :
Asthma
Cystic Fibrosis
Chronic Obstructive Pulmonary Diseases
(COPD), including
Bronchiectasis
Chronic Bronchitis
Pulmonary Fibrosis
